Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

Hepatology International

Volumn 4, Issue 4, 2010, Pages 732-740

  Yang, Jeng Fu ^a   Kao, Yi Hui ^b   Dai, Chia Yen ^a,c   Huang, Jee Fu ^b,c,d   Hsieh, Ming Yen ^a   Lin, Zu Yau ^a,c   Chen, Shinn Cherng ^a,c   Hsieh, Ming Yuh ^a,c   Wang, Liang Yen ^a,c   Chuang, Wan Long ^a,c   Yu, Ming Lung ^a,c,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

Author keywords

Adverse events (AEs); CHB; CHC; Peg IFN based therapy; Safety profile

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEARING IMPAIRMENT; HEART PALPITATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; ILEUS; INCIDENCE; INJECTION SITE INFLAMMATION; INSOMNIA; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN MANIFESTATION; TAIWAN; VIRUS LOAD; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 78649489024     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9208-0     Document Type: Article

References (40)

1. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733 1745 1:STN:280:DyaK1c%2FktFyjtA%3D%3D 10.1056/NEJM199712113372406 9392700 (Pubitemid 27527771)
2. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
3. IM Jacobson RS Brown Jr B Freilich, et al. 2007 Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 971 981 1:CAS:528:DC%2BD2sXht1aksrzE 10.1002/hep.21932 17894303 (Pubitemid 350144761)
4. V Di Marco PL Almasio D Ferraro, et al. 2007 Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial J Hepatol 47 484 491 17692985
5. A Abergel C Hezode V Leroy, et al. 2006 Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b J Viral Hepat 13 811 820 1:STN:280:DC%2BD28nntlWgtA%3D%3D 10.1111/j.1365-2893.2006.00768.x 17109680 (Pubitemid 44748285)
6. G Cooksley 2003 The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon J Hepatol 39 Suppl 1 S143 S145 1:CAS:528:DC%2BD3sXnt1yjur4%3D 10.1016/S0168-8278(03)00327-1 14708693
7. GK Lau T Piratvisuth KX Luo, et al. 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2695 1:CAS:528:DC%2BD2MXls1SktL8%3D 10.1056/NEJMoa043470 15987917 (Pubitemid 41007823)
8. P Marcellin GK Lau F Bonino, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 1:CAS:528:DC%2BD2cXns12rsr0%3D 10.1056/NEJMoa040431 15371578 (Pubitemid 39296307)
9. P Marcellin GK Lau S Zeuzem, et al. 2008 Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a Liver Int 28 477 485 1:CAS:528:DC%2BD1cXltlSltL4%3D 10.1111/j.1478-3231.2008.01696.x 18339074 (Pubitemid 351411133)
10. CH Chen PM Yang GT Huang HS Lee JL Sung JC Sheu 2007 Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants J Formos Med Assoc 106 148 155 10.1016/S0929-6646(09)60231-X 17339159
11. CY Dai WL Chuang CK Ho, et al. 2008 Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study J Hepatol 49 9 16 1:CAS:528:DC%2BD1cXmvFelsL8%3D 10.1016/j.jhep.2008.03. 016 18486265
12. MW Fried 2002 Side effects of therapy of hepatitis C and their management Hepatology 36 S237 S244 10.1002/hep.1840360730 12407599
13. RJ Aspinall PJ Pockros 2004 The management of side-effects during therapy for hepatitis C Aliment Pharmacol Ther 20 917 929 1:CAS:528: DC%2BD2MXhvV2htw%3D%3D 10.1111/j.1365-2036.2004.02192.x 15521838 (Pubitemid 39593272)
14. KL Lindsay C Trepo T Heintges, et al. 2001 A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 395 403 1:CAS:528: DC%2BD3MXmtVGqtLs%3D 10.1053/jhep.2001.26371 11481625 (Pubitemid 32702353)
15. S Zeuzem SV Feinman J Rasenack, et al. 2000 Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 1666 1672 1:CAS:528:DC%2BD3cXovVGhurY%3D 10.1056/NEJM200012073432301 11106715
16. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
17. M van Zonneveld HJ Flink E Verhey, et al. 2005 The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation Aliment Pharmacol Ther 21 1163 1171 10.1111/j.1365-2036.2005.02453.x 15854180 (Pubitemid 40646544)
18. WG Cooksley T Piratvisuth SD Lee, et al. 2003 Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 298 305 1:STN:280:DC%2BD3szksVOquw%3D%3D 10.1046/j.1365-2893.2003.00450.x 12823597 (Pubitemid 36801917)
19. HL Janssen G Gerken V Carreno, et al. 1999 Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 30 238 243 1:CAS:528:DyaK1MXksVOqsbs%3D 10.1002/hep.510300113 10385662 (Pubitemid 29300592)
20. GK Lau T Piratvisuth KX Luo, et al. 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2695 1:CAS:528:DC%2BD2MXls1SktL8%3D 10.1056/NEJMoa043470 15987917 (Pubitemid 41007823)
21. KR Reddy TL Wright PJ Pockros, et al. 2001 Efficacy and safety of pegylated (40-kDa) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C Hepatology 33 433 438 1:CAS:528:DC%2BD3MXht1agtbc%3D 10.1053/jhep.2001.21747 11172346 (Pubitemid 32119033)
22. PJ Pockros R Carithers P Desmond, et al. 2004 Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial Am J Gastroenterol 99 1298 1305 1:CAS:528:DC%2BD2cXmsl2ntLg%3D 10.1111/j.1572-0241. 2004.30306.x 15233669 (Pubitemid 39062267)
23. M Schaefer MA Engelbrecht O Gut, et al. 2002 Interferon alpha (IFNalpha) and psychiatric syndromes: a review Prog Neuropsychopharmacol Biol Psychiatry 26 731 746 1:CAS:528:DC%2BD38XltlGlt78%3D 10.1016/S0278-5846(01)00324-4 12188106 (Pubitemid 34615979)
24. CL Raison AS Borisov SD Broadwell, et al. 2005 Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction J Clin Psychiatry 66 41 48 1:CAS:528:DC%2BD2MXhsV2htLw%3D 10.4088/JCP.v66n0106 15669887
25. A Kleinman 2004 Culture and depression N Engl J Med 351 951 953 1:CAS:528:DC%2BD2cXnt12nur8%3D 10.1056/NEJMp048078 15342799 (Pubitemid 39166254)
26. K Weissenborn J Krause M Bokemeyer, et al. 2004 Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy J Hepatol 41 845 851 10.1016/j.jhep.2004.07.022 15519659 (Pubitemid 39434316)
27. MP McAndrews K Farcnik P Carlen, et al. 2005 Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors Hepatology 41 801 808 10.1002/hep.20635 15793853 (Pubitemid 40462942)
28. M Trippler Y Erim S Bein G Gerken JF Schlaak 2007 Identification of candidate genes for IFN-mediated depression in HCV patients J Hepatol 46 Suppl 1 S244 10.1016/S0168-8278(07)62244-2
29. JF Yang MY Hsieh NJ Hou, et al. 2009 Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice Aliment Pharmacol Ther 29 1000 1010 10.1111/j.1365-2036.2009.03957.x 19210290
30. MW Fried 2002 Side effects of therapy of hepatitis C and their management Hepatology 36 S237 S244 10.1002/hep.1840360730 12407599
31. V Balan D Schwartz GY Wu, et al. 2005 Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin Am J Gastroenterol 100 299 307 1:CAS:528: DC%2BD2MXisVeitL4%3D 10.1111/j.1572-0241.2005.40757.x 15667486 (Pubitemid 40314513)
32. KV Kowdley 2005 Hematologic side effects of interferon and ribavirin therapy J Clin Gastroenterol 39 S3 S8 1:CAS:528:DC%2BD2cXhtVKrtbbK 10.1097/01.mcg.0000145494.76305.11 15597025
33. MF Prummel P Laurberg 2003 Interferon-alpha and autoimmune thyroid disease Thyroid 13 547 551 1:CAS:528:DC%2BD3sXmsFCrur4%3D 10.1089/ 105072503322238809 12930598
34. M Deutsch S Dourakis EK Manesis, et al. 1997 Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy Hepatology 26 206 210 1:STN:280:DyaK2szlslWhsg%3D%3D 10.1002/hep.510260127 9214471
35. O Dalgard K Bjoro K Hellum, et al. 2002 Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy J Intern Med 251 400 406 1:CAS:528:DC%2BD38XkslSlur4%3D 10.1046/j.1365-2796.2002.00974.x 11982739 (Pubitemid 34534115)
36. WS Ayoub EB Keeffe 2008 Review article: current antiviral therapy of chronic hepatitis B Aliment Pharmacol Ther 28 167 177 1:CAS:528: DC%2BD1cXps1Gmsb0%3D 10.1111/j.1365-2036.2008.03731.x 18466358 (Pubitemid 351861968)
37. A Craxi WG Cooksley 2003 Pegylated interferons for chronic hepatitis B Antiviral Res 60 87 89 1:CAS:528:DC%2BD3sXpt1eqsro%3D 10.1016/j.antiviral.2003. 08.015 14638403 (Pubitemid 37452451)
38. R Guan 2005 Treatment of chronic hepatitis B infection using interferon Med J Malaysia 60 Suppl B 28 33 16108170
39. T Witthoft B Moller KH Wiedmann, et al. 2007 Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial J Viral Hepat 14 788 796 10.1111/j.1365-2893.2007.00871.x 17927615 (Pubitemid 47561583)
40. P Martin DM Jensen 2008 Ribavirin in the treatment of chronic hepatitis C J Gastroenterol Hepatol 23 844 855 1:CAS:528:DC%2BD1cXptFyls7o%3D 10.1111/j.1440-1746.2008.05398.x 18565019 (Pubitemid 351806583)